RESUMEN
With increasing resistance to existing antimalarials, there is an urgent need to discover new drugs at affordable prices for countries in which malaria is endemic. One approach to the development of new antimalarial drugs is to improve upon existing antimalarial agents, such as the tetracyclines. Tetracyclines exhibit potent, albeit relatively slow, action against malaria parasites, and doxycycline is used for both treatment (with other agents) and prevention of malaria. We synthesized 18 novel 7-position modified tetracycline derivatives and screened them for activity against cultured malaria parasites. Compounds with potent in vitro activity and other favorable drug properties were further tested in a rodent malaria model. Ten compounds inhibited the development of cultured Plasmodium falciparum with a 50% inhibitory concentration (IC50) after 96 h of incubation of <30 nM, demonstrating activity markedly superior to that of doxycycline (IC50 at 96 h of 320 nM). Most compounds showed little mammalian cell cytotoxicity and no evidence of in vitro phototoxicity. In a murine Plasmodium berghei model, 13 compounds demonstrated improved activity relative to that of doxycycline. In summary, 7-position modified tetracyclines offer improved activity against malaria parasites compared to doxycycline. Optimized compounds may allow lower doses for treatment and chemoprophylaxis. If safety margins are adequate, dosing in children, the group at greatest risk for malaria in countries in which it is endemic, may be feasible.
Asunto(s)
Antimaláricos/farmacología , Malaria/tratamiento farmacológico , Malaria/prevención & control , Plasmodium berghei/efectos de los fármacos , Tetraciclinas/farmacología , Animales , Resistencia a Medicamentos , Ratones , Pruebas de Sensibilidad ParasitariaRESUMEN
LcrF (VirF), a transcription factor in the multiple adaptational response (MAR) family, regulates expression of the Yersinia type III secretion system (T3SS). Yersinia pseudotuberculosis lcrF-null mutants showed attenuated virulence in tissue culture and animal models of infection. Targeting of LcrF offers a novel, antivirulence strategy for preventing Yersinia infection. A small molecule library was screened for inhibition of LcrF-DNA binding in an in vitro assay. All of the compounds lacked intrinsic antibacterial activity and did not demonstrate toxicity against mammalian cells. A subset of these compounds inhibited T3SS-dependent cytotoxicity of Y. pseudotuberculosis toward macrophages in vitro. In a murine model of Y. pseudotuberculosis pneumonia, two compounds significantly reduced the bacterial burden in the lungs and afforded a dramatic survival advantage. The MAR family of transcription factors is well conserved, with members playing central roles in pathogenesis across bacterial genera; thus, the inhibitors could have broad applicability.
Asunto(s)
Proteínas Bacterianas/antagonistas & inhibidores , Bencimidazoles/farmacología , Neumonía Bacteriana/patología , Factores de Transcripción/antagonistas & inhibidores , Infecciones por Yersinia pseudotuberculosis/patología , Yersinia pseudotuberculosis/efectos de los fármacos , Yersinia pseudotuberculosis/patogenicidad , Animales , Antibacterianos/administración & dosificación , Antibacterianos/síntesis química , Antibacterianos/química , Antibacterianos/farmacología , Proteínas Bacterianas/metabolismo , Bencimidazoles/administración & dosificación , Bencimidazoles/síntesis química , Bencimidazoles/química , Línea Celular , Modelos Animales de Enfermedad , Femenino , Humanos , Pulmón/microbiología , Macrófagos/microbiología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Neumonía Bacteriana/tratamiento farmacológico , Neumonía Bacteriana/microbiología , Neumonía Bacteriana/mortalidad , Factores de Transcripción/metabolismo , Resultado del Tratamiento , Virulencia , Yersinia pseudotuberculosis/metabolismo , Infecciones por Yersinia pseudotuberculosis/tratamiento farmacológico , Infecciones por Yersinia pseudotuberculosis/microbiología , Infecciones por Yersinia pseudotuberculosis/mortalidadRESUMEN
ExsA is a multiple adaptational response (MAR) transcription factor, regulating the expression of a virulence determinant, the type III secretion system (T3SS) in Pseudomonas aeruginosa. Non-cytotoxic, non-antibacterial N-hydroxybenzimidazoles were identified as effective inhibitors of ExsA-DNA binding, and their potential utility as anti-virulence agents for P. aeruginosa was demonstrated in a whole cell assay. Select N-hydroxybenzimidazole inhibitors were stable in an in vitro human liver microsomal assay.
Asunto(s)
Bencimidazoles/antagonistas & inhibidores , Pseudomonas aeruginosa/efectos de los fármacos , Factores de Transcripción/antagonistas & inhibidores , Virulencia/efectos de los fármacos , Humanos , Microsomas Hepáticos/efectos de los fármacos , Pseudomonas aeruginosa/metabolismo , Pseudomonas aeruginosa/patogenicidadRESUMEN
LcrF, a multiple adaptational response (MAR) transcription factor, regulates virulence in Yersinia pestis and Yersinia pseudotuberculosis. In a search for small molecule inhibitors of LcrF, an acrylic amide series of N-hydroxybenzimidazoles was synthesized and the SAR (structure-activity relationship) was examined. Selected test compounds demonstrated inhibitory activity in a primary cell-free LcrF-DNA binding assay as well as in a secondary whole cell assay (type III secretion system dependent Y. pseudotuberculosis cytotoxicity assay). The inhibitors exhibited no measurable antibacterial activity in vitro, confirming that they do not target bacterial growth. These results demonstrate that N-hydroxybenzimidazole inhibitors, exemplified by 14, 22, and 36, are effective antivirulence agents and have the potential to prevent infections caused by Yersinia spp.
Asunto(s)
Antibacterianos/química , Antibacterianos/farmacología , Proteínas Bacterianas/antagonistas & inhibidores , Bencimidazoles/química , Bencimidazoles/farmacología , Transactivadores/antagonistas & inhibidores , Yersinia pestis/efectos de los fármacos , Yersinia pseudotuberculosis/efectos de los fármacos , Animales , Antibacterianos/síntesis química , Antibacterianos/uso terapéutico , Proteínas Bacterianas/metabolismo , Bencimidazoles/síntesis química , Bencimidazoles/uso terapéutico , Línea Celular , Sistema Libre de Células/metabolismo , ADN/metabolismo , Descubrimiento de Drogas , Concentración 50 Inhibidora , Ratones , Peste/tratamiento farmacológico , Relación Estructura-Actividad , Transactivadores/metabolismo , Virulencia/efectos de los fármacos , Yersinia pestis/patogenicidad , Yersinia pseudotuberculosis/patogenicidadRESUMEN
MarA, SoxS and Rob are transcription factors belonging to the AraC family. While these proteins have been associated historically with control of multiple antibiotic resistance, and tolerance to oxidative stress agents and organic solvents, only a paucity of experimental data support a role in regulating virulence. Clinical Escherichia coli isolates, and isogenic strains lacking marA, soxS and rob, were studied in a murine model of ascending pyelonephritis, which is a clinically relevant model of urinary tract infection. Organisms lacking all three transcription factors (triple knockouts) were significantly less virulent than parental strains, and complementation studies demonstrated that the addition of marA, soxS and rob individually restored wild-type virulence in the triple-knockout strain. Deletion of soxS or rob alone was more detrimental than the removal of marA. Thus, all three proteins contribute to virulence in vivo.